The active substance of Mucoflux is cyclidrol (sobrerol), a synthetic compound chemically defined as: D,L-trans-1-methyl-4-(2-hydroxy-isopropyl)-cyclohex -1,2-en-6-ol.
Cyclidrol lowers the viscosity of mucus, favouring the expulsion of mucous clusters from the respiratory tract. It does not effect the alveolar surfactant or the ciliary movements of the bronchotracheal mucosa. It has no bronchoconstrictory effects.
Because of these properties and of the low toxicity and good tolerability, cyclidrol is an effective and safe agent in all those disorders where the respiratory tract is obstructed or overloaded by an excess of mucus, that hinders the normal flow of air. Mucoflux has therefore two main actions:
- cleansing since it allows and facilitates the removal of mucous and mucopurulent secretions
- eupneic, since it improves the respiratory parameters.
PHARMACOKINETIC PROPERTIES
Cyclidrol is rapidly absorbed by the first tract of the gastro-enteric apparatus. The maximum absorption has been observed at 60'.
Cylidrol is rapidly distributed. The rapid distribution is confirmed by the high levels of cyclidrol found in the bronchial mucus already one hour after the administration. In man, the plasmatic half-life of cyclidrol administered by i.v. route is 1.60 hours, while in the mucus is 10.82 hours. By oral administration the plasmatic half-life of cyclidrol is 2.39 hours and 2.98 hours in the bronchial mucus.
The biotransformation of cyclidrol in man consists of two reactions phases: a phase I reaction leading to carvone and a phase II reaction leading to the conjugation with glucuronic acid. A total of 9 metabolites have been found in man and animal.
In man cyclidrol is excreted nearly exclusively through the kidneys as free cyclidrol, glucurono-conjugates cyclidrol and carvone.
INDICATIONS
Cyclidrol is a mucolytic agent which lowers the viscosity of mucus and is indicated in the acute and chronic disorders of the respiratory tract characterized by excessive, viscous mucus.
CONTRA-INDICATIONS
Known hypersensitivity to the ingredients of the product.
The drug is contraindicated in children younger than 2 years.
SIDE-EFFECTS
Nausea and gastrointestinal disorders.
PRECAUTIONS/WARNINGS
Patients with renal failure should be monitored while on treatment with Mucoflux.
DRUG INTERACTIONS
No drug interactions have so far been reported. Mucoflux may be combined with antibiotics, bronchodilators, anti-asthmatic and antitubercolous agents.
PREGNANCY AND LACTATION
Mucoflux is exempt from mutagenic and teratogenic potential, nevertheless it should be administered to pregnant women only if necessary and under medical monitoring.
No contra-indications during lactation are known.
Drugs and medications - Mucoflux - Medical Explorer
ชนิดน้ำเชื่อม : รับประทานครั้งละ 10 – 20 ml วันละ 2 ครั้ง
เด็กอายุเกิน 2 ขวบ
ชนิดน้ำเชื่อม : รับประทานครั้งละ 10 ml วันละ 2 ครั้ง
เด็กอายุต่ำกว่า 2 ขวบ
ชนิดน้ำเชื่อม : รับประทานครั้งละ 5 ml วันละ 2 ครั้ง
Cyclidrol is a mucolytic agent which lowers the viscosity of mucus and is indicated in the acute and chronic disorders of the respiratory tract characterized by excessive viscous mucus.
Mechanism of Action
Bronchial cleanser. Cyclidrol allows and facilitates the removal of mucous and mucopurulent secretions and improves the respiratory parameter.
Capsule 100 mg:
Adults: 2 capsules twice daily for ≥2 weeks,
Syrup 80 mg/10 mL x 60 mL.:
Adults: 1-2 tsp (10-20 mL) twice daily for ≥2 weeks,